Business
Scancell Appoints Dr Nermeen Varawalla as CMO
Scancell Appoints Dr Nermeen Varawalla as CMO.
About this update from Scancell Holdings Plc
[{"type":"text","content":"\n\nThe Scancell Appoints Dr Nermeen Varawalla as Chief Medical Officer released today at 07:00hrs under RNS no: 2949Y was released in error and should be disregarded. The full correct version of the announcement appears below.\n \n30 July 2024\n \nScancell Holdings plc\n(\"Scancell\" or the \"Company\")\n \nScancell Appoints Dr Nermeen Varawalla as Chief Medical Officer\n \nDr Varawalla joins with over 25 years of experience across global large pharma, healthcare business consultancy and clinical trial services\n \nAppointment enhances Scancell's capabilities for the registration of the adaptive randomised controlled Phase 2/3 SCOPE-2 trial following clinical results from SCIB1 and iSCIB1+ cohorts \n \nScancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer, today announces the appointment of Dr Nermeen Varawalla as Chief Medical Officer (CMO), effective immediately.\n \nDr Varawalla has over 25 years of healthcare industry experience in senior leadership positions at global large pharma, healthcare business consultancy and clinical trial services. She brings deep expertise in clinical trial planning and medical affairs, with a strong track record in the execution of global drug development programmes, including numerous registration studies in oncology.\n \nDr Varawalla has experience of building cross-functional, high-performing teams in both Europe and the USA and progressing clinical assets through to regulatory and commercial success in a number of companies, including Atlantic Healthcare plc, BTG Ltd and, most recently, Relief Therapeutics (SIX:RLF). While at Atlantic Healthcare, Dr Varawalla collaborated across high-performing teams to design FDA registration clinical development programmes and lead non-dilutive fundraising efforts.\n \nAs Senior Vice President, Head of Clinical Development & Biometrics at BTG, an international specialty pharmaceutical and medical device company acquired by Boston Scientific Corporation (NYSE: BSX) in 2019 for $4.2 billion, Dr Varawalla was instrumental in driving transformational change to clinical development and was responsible for the design and execution of phase 3 clinical registration trials in hepatic and colorectal cancer for a radioembolisation therapy wh...